Skip to main content
news
A sign of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS/Tingshu Wang

 

Sinopharm Group, an investment consortium led by Sinopharm Group, and China Traditional Chinese Medicine Holdings (China TCM) recently announced a take-private deal for the Hong Kong-listed China TCM through a scheme of arrangement.

The total transaction amount is approximately $2 billion, marking the largest take-private deal announced so far this year.

Haiwen & Partners served as legal counsel to one of the consortium members of the offeror, China State-Owned Enterprise Mixed Ownership Reform Fund, providing legal services in both Mainland China and Hong Kong. Meanwhile, Clifford Chance acted as the legal advisor to CITIC Securities, the financial advisor to the offeror.

The consortium behind the offeror comprises the Mixed Ownership Fund, Sinopharm (Hong Kong), Advanced Manufacturing Industry Investment Fund Phase II, China Reform Development Investment Management, Chongqing Fuling Industry Development Group, and Red Investment Limited.

China TCM primarily engages in the production and sale of traditional Chinese medicine and pharmaceutical products, focusing on Chinese medicine granules, patent medicines, and Chinese medicinal slices. China TCM has been listed in Hong Kong since 1993.

The Haiwen team was led by partners Wu Zuolong and Lin Xixiang, while partner Tommy Tam led the Clifford Chance team.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

Khaitan, JSA, Hogan Lovells guide $515 mln Waaree IPO

by Nimitt Dixit |

Khaitan & Co has advised Waaree Energies, India's largest manufacturer and exporter of solar modules, on its $515 million initial public offering, with JSA Advocates & Solicitors and Hogan Lovells guiding the bookrunning lead managers.

Deals

CAM, Khaitan guide Adani-backed Renew Exim’s $380 mln ITD acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Adani Group's Dubai-based firm Renew Exim DMCC on its acquisition of a 46.64 percent stake in ITD Cementation India for around $380 million from Italian-Thai Development Public Company, who was represented by Khaitan & Co.

Deals

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.